Johnson & Johnson and Merck end Drug Dispute

As reported by The Wall Street Journal, the global pharmaceutical companies, Johnson & Johnson and Merck have ended their dispute over the marketing of the arthritis drugs Remicade and Simponi.

It has been agreed that Merck will market the drugs in Europe, Russia and Turkey and will pay $500 million to J&J, who will market them in Canada, Central and South America, Africa, the Middle East and the Asia-Pacific region. Merck will then split the profits from the sales of the drugs.

The dispute originally arose after Merck acquired Schering-Plough which had a marketing agreement with J&J.

Are you looking for a new position in the pharmaceutical industry? Click  here to search our current pharmaceutical jobs online now.

Posted in: General
CK Logo in place of featured image